Although the positive effects of vaginal estrogens and the selective estrogen receptor modulator, ospemifene (OS), on the vaginal epithelium are well recognized, less is known regarding the effects of these therapies on the lower urinary tract or vaginal muscularis. Clinical evidence suggests that vaginally administered estrogen may improve overactive bladder-related symptoms. The objective of this study was to compare the effects of OS, vaginal conjugated equine estrogens (CEE), or both on the vaginal wall and lower urinary tract in a rat model of menopause. Contractile force of the bladder neck, dome, and external urethral sphincter at optimal field stimulation did not differ significantly among treatment groups. Pharmacologic responses to atropine, carbachol, and potassium chloride were similar among groups. Vaginal epithelial thickness and differentiation were differentially regulated by CEE or OS. Ospemifene altered epithelial differentiation pathways in vaginal epithelium in a unique way, and these effects were additive with local CEE. Unless contraindicated, the beneficial effects of vaginal CEE on the vaginal wall outweigh those of OS.
Introduction
Decreasing levels of estrogen in the postmenopausal period may result in regression of the vaginal epithelium of women, manifesting clinically as vulvovaginal atrophy (VVA). In fact, as many as 50% of postmenopausal women experience bothersome symptoms of VVA (vaginal dryness, itching, burning, or dyspareunia) [1, 2] . Preoperative application of vaginal conjugated equine estrogens (CEE) has recently been shown to have beneficial effects on the vaginal wall, potentially improving substrate for suture placement and maintenance of connective tissue integrity in surgical reconstructive procedures for pelvic organ prolapse [3] . Concerns regarding effects of systemic estrogen on cardiovascular events and breast cancer have led to the development of alternative therapeutic agents to alleviate adverse effects of estrogen on certain target tissues such as the breast C The Authors 2016. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please journals.permissions@oup.com 81 and endothelial cells. Further, oral agents are sought to avoid application of local estrogen gels, creams, and rings which may result in systemic absorption.
Selective estrogen receptor modulators (SERMs), also referred to as estrogen receptor agonist-antagonists (ERAAs), are nonsteroidal estrogen receptor ligands that produce either agonist or antagonist estrogen effects in target tissue depending on their chemical conformation [4] . Ospemifene (OS) is a chloroethane triphenylethylene SERM with an ethooxyethanol side chain that binds ERα and ERβ at concentrations comparable to those seen with tamoxifen and toremifene [5, 6] . After phase II and III clinical trials demonstrated significant improvement in bothersome VVA symptoms with increased superficial and intermediate vaginal epithelial cells, OS was FDA approved for treatment of VVA symptoms in postmenopausal women [7] [8] [9] . Animal studies have shown that OS also reverses ovariectomy-induced bone loss in rats and antitumor effects in the rat (7, 12 -dimethylbenz(a)anthracene)-induced mammary cancer model [4, 10] . In addition, a preclinical rat model of menopause has proven highly predictive of SERM activity in postmenopausal VVA. For example, histologic analyses of the vagina from animals treated with OS demonstrated an increase in vaginal epithelium height and vaginal weight. Dose responses for OS in the rat were consistent with that observed in clinical studies [11] . Ospemifene dose-response studies were performed with comparisons to oral estradiol and raloxifene, but not vaginal CEE, the most commonly used product for VVA. Using a similar rat model of menopause, we recently demonstrated that low-dose vaginal CEE resulted in increased vaginal epithelial thickness and increased total and cross-linked collagen content compared with placebo and that this effect was superior to that of systemic estrogen [12] . In addition, we reported that, in women, vaginal CEE increases collagen mRNA and collagen type I content in the vaginal wall accompanied by significant increases in thickness of the muscularis [3] .
Although the positive effects of vaginal CEE and OS on the vaginal epithelium are recognized, less is known regarding the effects of these therapies on the lower urinary tract or vaginal muscularis, in which estrogen receptors are expressed. There is some clinical evidence that suggests vaginally administered 17β-estradiol [13, 14] , or vaginal estriol [15] may improve overactive bladder (OAB)-related symptoms and help decrease recurrent urinary tract infections [16, 17] . Here, we sought to explore the specific tissue effects of OS on the structure and function of the vaginal wall and on contraction/relaxation of the bladder and external urethral sphincter (EUS). Therefore, the objective of this study was to compare the effects of oral OS, vaginal CEE, or both on the histomorphology, biomechanical properties, and collagen content of the vaginal wall in a rat model of menopause. In addition, we sought to examine the effects of these therapies on the neurophysiologic responses of the bladder neck, dome, and EUS. Finally, we aimed to explore the effects of combining different ER agonists/antagonists with OS therapy to test the hypothesis that OS and estrogen differentially activate ER subtypes and thereby alter epithelial differentiation pathways.
Materials and methods
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Southwestern Medical Center at Dallas. Animals were handled and euthanized in accordance with the standards of humane animal care as defined by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. A total of 72 virginal Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) at 12-14 weeks of age were housed in IACUC-approved facilities under a 12-h light cycle at 22
• C.
Treatment groups
Study animals underwent bilateral oophorectomy via bilateral 1-cm flank incisions. For the first experiment, 2 weeks after ovariectomy, animals were randomly assigned to four different treatment groups: Placebo (oral placebo + vaginal placebo, n = 18), CEE (vaginal CEE + oral placebo, n = 18), OS (oral OS + vaginal placebo, n = 18), or OS-CEE (oral OS + vaginal CEE, n = 18). Ospemifene (OS, Sigma Aldrich, St. Louis, MO) was dissolved in ethanol, diluted in polyethylene glycol (PEG) vehicle, and given via oral gavage at a dose of 1 mg/kg/day in a volume of 3 mL/kg. This dosing is based on a previous animal study indicating that the anticipated daily dose to treat postmenopausal VVA in humans (60 mg) results in 0.86-1 mg/kg/day [11] . Systemic oral preparations of OS were chosen because (i) oral and vaginal OS demonstrate similar effects on the vaginal wall [11] , and (ii) this is the formulation used in clinical practice. For oral placebo, a PEG vehicle solution was given by oral gavage following the same schedule as the OS treatment group. Conjugated equine estrogen cream (Pfizer Pharmaceuticals, New York, NY) was administered vaginally in low doses (625 ng/dose in 100 mg of cream) daily for 1 week, then every other day for 2 weeks as described previously [12, 18, 19] . Application of vaginal placebo cream followed the same schedule as the CEE treatment group. Topical benzoin was applied to the vulva to discourage ingestion of the cream. Thus, in this study, all animals received vaginal and oral treatments. Unpublished data indicate that oral + vaginal placebo does not alter vaginal mechanics, urethral histology, vaginal histology, or collagen content compared with untreated ovariectomized controls. For experiment 2, in which we compared the effects of oral OS or systemic ERAAs, 2 weeks after ovariectomy, 22 animals were randomly assigned to six different treatment groups: Placebo (oral placebo + s.c. placebo, n = 3), OS (oral OS + s.c. placebo, n = 3), OS + tetrahydrochrysene (oral OS + s.c. THC, n = 4), OS + methyl-piperidino-pyrazole (oral OS + s.c. MPP, n = 4), diarylpropionitrile (s.c. DPN, n = 4), or 4,4 ,4 -(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, (s.c. PPT, n = 4). Ospemifene (Sigma Aldrich, St. Louis, MO) was administered as described above. Tetrahydrochrysene, MPP, DPN, and PPT (Tocris Bioscience, Avonmouth, Bristol, UK) was dissolved in DMSO and given in 100 μl doses subcutaneously at 1 mg/kg/day. Treatments were given daily for 7 days, and then animals were sacrificed for histologic analysis of the vaginal wall.
To compare oral OS with vaginal ERAAs, 2 weeks after ovariectomy, 15 animals were randomly assigned to six different treatment groups: OS (oral OS + s.c. placebo, n = 3), OS + THC (oral OS + vaginal THC, n = 3), OS + MPP (oral OS + vaginal MPP, n = 3), OS + THC + MPP (oral OS + vaginal THC/MPP, n = 3), or DPN (vaginal DPN, n = 3). Tetrahydrochrysene, MPP, DPN, and PPT (Tocris Bioscience, Avonmouth, Bristol, UK) were dissolved in DMSO and added to eucerin cream to create 9 mM, 9 mM, and 300 μM vaginal formulations (respectively). Treatments were given daily for 5 days, and then animals were sacrificed for histologic analysis of the vaginal wall.
Tissue processing
Animals were euthanized and tissues collected 3 weeks after initiation of treatment. Once the abdominal cavity was opened, the pubic symphysis was disarticulated, and the uterine horns, bladder, cervix, and vagina dissected down to the perineal skin. Care was taken to preserve the integrity of the EUS upon separating the bladder and urethra from the vagina. Using microsurgical instruments and a dissection microscope, the EUS was dissected in its entirety from the urethra, maintaining its tubular structure, and mounted for electrical field stimulation (EFS). Two bladder rings were excised for EFS testing: one at the level of the bladder neck and another at the bladder dome. Uterine horns and cervix were sharply dissected from the vagina. Gross weights of all pelvic organs were recorded. Two sections of uterus (one from each uterine horn) were submitted for histologic processing. Two vaginal rings were excised at the junction of the upper and mid-vagina: one was mounted for biomechanical testing and another submitted for histopathologic processing. The remainder of the vaginal canal was opened longitudinally, the epithelium scraped off using a scalpel, and the remaining vaginal muscularis (including lamina propria and adventitia) snap-frozen in liquid nitrogen and stored at -80 • C. In this work, unless specified otherwise, muscularis refers to lamina propria, muscular bundles, and adventitia. In a subset of animals, the vagina, urethra, and bladder were removed en bloc and submitted for histological processing, providing serial 1 mm transverse sections from the distal urethra to the bladder dome (n = 5 per group).
Protein extraction and immunoblotting
Frozen vaginal tissue was pulverized using a liquid nitrogen-chilled mortar and pestle. The pulverized tissue was then homogenized in radioimmunoprecipitation assay buffer containing protease inhibitors (protease inhibitors; Roche Diagnostics, Mannheim, Germany) (16 mM potassium phosphate pH 7.8, 0.12 M NaCl, 1 mM EDTA, 0.1 mM PMSF, 10 μg/mL pepstatin A, and 10 μg/mL leupeptin), and centrifuged at 10,000 × g. A bicinchoninic acid (colorimetric) protein assay was used to quantify protein concentrations, using standard curves of bovien serum albumin in appropriate buffers. Protein samples (10 μg/lane) were applied to 4-15% gradient polyacrylamide gels (Bio-Rad, Hercules, CA), separated by electrophoresis, and transferred to nitrocellulose membranes overnight at 4
• C. Thereafter, membranes were incubated with blocking buffer (tris-buffered saline-Tween 20 with 5% nonfat milk) for 1 h. An affinity-purified rabbit antibody against rat and mouse collagen type 1 (COL1a1) (Merck-Millpore, Darmstadt, Germany) and an ascites-grade mouse antibody against human and rat collagen type 3 (COL3a1) (USBiological, Salem, MA) was used for immunoblotting (Table 1) . Membranes were incubated in primary antibody (COL1a1, 1:2,000; COL3a1, 1:200) for 60 min on an orbital shaker at 37
• C, and then serially washed with TBS-T, followed by treatment with secondary antibody (COL1a1, goat IgG antirabbit, 1:10,000; COL3a1, goat IgG antimouse 1:10,000) at room temperature for 1 h. Membranes were then washed again with TBS-T and then incubated with Chemiluminescence Reagent (Thermo Scientific, Rockford, IL) for 2 min. Signal strength was captured using Fujifilm LAS-3000 image capture system. Protein band density was then calculated using Fujifilm Multigauge Program version 3.0 and normalized to total protein as determined by side-by-side coomassie-stained gels.
Quantification of mRNA
The relative levels of collagen messenger RNA in vaginal tissues were determined using quantitative polymerase chain reaction. Tissues were pulverized using liquid nitrogen and chilled mortar and pestle, then homogenized in Trizol reagent (RNA Stat-60, Amsbio, Abingdon, UK) and RNA extracted according to the manufacturer's protocol. Complementary DNA synthesis was performed using 1 μg of total RNA in a reaction volume of 10 μL, containing 5× buffer, 0.1 M dithiothreitol, 0.3 μg/μL random primers, 10 mM deoxynucleotide triphosphates, 40 U RNase inhibitor (Invitrogen), and 200 U reverse transcriptase enzyme (Invitrogen). PCR reactions were performed in the ABI Prism 7000 sequence-detection system (Applied Biosystems). The reverse transcription product from 25 ng RNA was used as a template, and reaction volumes (15 μL) contained Master Mix (Applied Biosystems) and primer concentrations of 900 nM. Cycling conditions included: 2 min at 50
by 10 min at 95 • C; then 40 cycles of 15 s at 95
• C, and 1 min at 60
• C. Amplicon detection was via SYBR Green. Gene expression was normalized to expression of the two housekeeping genes, cyclophilin A (CYPA) and hypoxanthine-guanine phosphoribosyltransferse (HPRT), which were invariant among samples. A preprogrammed dissociation protocol was used after amplification to ensure that all samples exhibited a single amplicon. mRNA levels were determined using the ddCt method (Applied Biosystems) and expressed relative to an external calibrator present on each plate. Primers used in this study are reported in reference [12] . All primer sets were tested to ensure that efficiency of amplification over a wide range of template concentrations was equivalent to that of CYPA and HPRT.
Biomechanical testing
Viscoelastic properties of individual vaginal rings were quantified as previously described [12, 20] . Briefly, tissue rings were suspended between two stainless steel wire mounts, attached to a steel rod apparatus with a calibrated mechanical drive, and to a force transducer. All tissues were kept in a physiologic salt solution (NaCl 120 • C with 95% O2 and 5% CO2. Once acclimated in the water bath, each vaginal ring was then equilibrated to slack length (ring diameter at resting tone) as measured by the calibrated mechanical drive. Tissues were then serially stretched in 1 mm increments at 30-s intervals between each increment in order to permit stabilization of forces before each subsequent distention. The distention process persisted until tissue failure or force generated plateaued. Stress (force per tissue cross-sectional area) was calculated in kPa and plotted against change in length, producing a sigmoid-shaped curve. Tissue stiffness was calculated from the slope of the linear portion of the curve.
Histomorphology
Uterine and vaginal tissue rings were fixed in neutral buffer formalin (10%) for 24 h, processed in 50% ethanol and embedded in paraffin blocks. Cross-sections of each tissue ring were stained with hematoxylin and eosin and Masson's trichrome stain. Images of stained sections were captured using a Nikon E1600 microscope and analyzed using Nikon NIS Elements AR software (Melville, NY) and Image J software (Image J 1.46r, NIH). The distance of at least 6-10 measurements from the lumen cell surface to the basement membrane were quantified to provide the mean epithelial thickness in each specimen. Similarly, the distance between the basement membrane and edge of the muscular bundles was determined. Thickness of the total vaginal wall (including adventitia, muscularis, lamina propria, and epithelium) was also quantified. In a subset of 24 animals, the vagina, urethra, and bladder were removed en bloc and submitted for histological processing only. Tissues were fixed in a neutral buffer formalin (10%) for 24 h. Formalin-fixed, paraffin-embedded tissues were sectioned in transverse fashion in serial 1-mm increments from the distal urethra to the bladder dome and stained with hematoxylin and eosin, and Masson's trichrome stain. Images of stained sections were then captured using a Nikon E1600 microscope and analyzed using Nikon NIS Elements AR software (Melville, NY) and Image J software (ImageJ 1.46r, NIH). Urothelial thickness in the urethra and in the bladder dome was measured (as a mean of 3-4 measurements per section, throughout the specimen).
Hydroxyproline assays
Collagen solubility measurements [21] were conducted using hydroxyproline assays. Vaginal tissue weights were recorded before and after tissue lyophilization. PBS with PI (1 tablet/10 mL) was added to the lyophilized tissues for homogenization at 4
• C for 24 h, then centrifuged (21,000× g) and the supernatant saved as Fraction A (newly synthesized, noncross-linked collagen fraction). The remaining pellet was washed with a solution of water and PI, and then extracted using a solution of 0.5 M acetic acid and PI at 4
• C for 24 h with rotation, centrifuged and the supernatant saved as Fraction B (denatured mature collagen). The resulting tissue pellet was saved as Fraction C (mature, cross-linked collagen). Finally, a solution of 6 M HCl was added to all fractions and incubated at 100
• C overnight to measure hydroxyproline content by the chloramine (13)-T method. Hydroxyproline values were converted to collagen (×7.6 constant) and normalized to tissue wet and dry weights.
Lower urinary tract

Electrical field stimulation
The dissected EUS, bladder neck, and bladder dome samples were mounted as a ring between two stainless steel wires, one of which was fastened to steel rods mounted with calibrated mechanical drives and the other to a force transducer, as previously described [22, 23] . Tissues were maintained in water-jacketed baths of physiologic salt solution at 37
• C with 95% O2 and 5% CO2. For EFS, platinum wire electrodes were mounted in parallel to the suspended tissues. These electrodes were coupled to an isolated pulse stimulation and a Grass stimulator (Grass FT.03C, Grass Instruments, Quincy, MA) through a current-boosting amplifier (Hewlet-Packard Bipolar, PaloAlto, CA). In addition, tissue stimulation was controlled by driver and signal conditioning/amplifier units (Grass DC driver amplifiers 7DAE or 7DAF, Grass low-level DC Amplifiers 7PIF, Grass Instruments). A multichannel analog-to-digital computer interface (National Instruments PCI-6032E, Austin, TX) was used to capture analog force signals. A computer program (National Instruments PC-DIO-24 Digital I/O Board controlling a specially designed circuit) interfaced to the stimulator voltage source was used to control the stimulation patterns. Finally, a central computerized controller was used to deliver precise stimulation, duration, and frequencies. The voltage and pulse duration (milliseconds) was set manually by altering settings on the stimulator unit. Baseline resting tension was set on each tissue. Twitch tension of the EUS was determined after stimulation with one square 0.4 millisecond pulse of 50 V at 10 Hz. Force-frequency response curves were then obtained for the bladder neck, dome, and EUS by stimulation at 10- 
Responsiveness to pharmacologic agents
Bladder neck and bladder dome tissues were maintained in the same conditions as for EFS. A nonselective muscarinic agonist, carbachol (10 −8 -10 −4 M) was added to each tissue bath, and dose-response curves were conducted to determine the EC 50 (half maximal effective concentration) and maximal contractile response. Resistance of maximal EFS contractions to the agent atropine, a competitive antagonist of the muscarinic acetylcholine receptors, was determined by stimulation of the tissue 20 min after treatment with atropine (10
This allowed determination of atropine-independent contractions. At the end of each experiment, a 100 mol/L KCL solution substituted isotonically with NaCl was added to each bath to determine contractions resulting from potassium-induced tissue depolarization, independent of electrical stimulation.
Tissue cross-sectional area
The cross-sectional area (cm 2 ) of each tissue ring was calculated using the formula W/L × D (W = tissue wet weight in grams, L = final tissue stretched length in cm, D = tissue density, 1.05 g/cm 3 ) [22] . The active contractile stress (force per cross-sectional area) for each tissue could then be compared at optimal length L o for maximal force.
Statistical analysis
Data are presented as mean ± standard error mean (SEM). Oneway analysis of variance (ANOVA) and nonparametric (Kruskal Wallis) testing was performed, as appropriate, for multiple group comparisons. With a P < 0.05 significance, post-testing between groups was performed using Tukey test for normally distributed data and Dunn's tests for nonparametric distributions with placebo designated as the control group.
Results
Effect of ospemifene and vaginal conjugated equine estrogens on the lower urinary tract
To determine if OS, vaginal CEE, or the combination of OS + CEE altered contractile function of the lower urinary tract, ovariectomized rats were treated with oral vehicle/vaginal placebo, OS, CEE, or OS + CEE for 3 weeks. Thereafter, contractile force of the bladder neck, dome, and EUS was quantified during EFS. Frequencyforce and voltage-force relationships were determined from 10-140 Hz and 10-60 V (Figure 1 ). The dose-response relationships were virtually identical among treatment groups, and maximal EFS-stimulated force development was similar among treatment groups in smooth muscles (bladder neck and dome; Table 2 ) and striated sphincter (EUS; Table 2 ). Force of contractions was 8-10-fold greater in the dome relative to the bladder neck. To determine the fraction of force elicited by release of acetyl choline from cholinergic neurons within the bladder wall, field stimulation was conducted before and after muscarinic blockade with atropine. Overall, atropine inhibited a greater percentage of contraction in the neck relative to the dome (51 vs. 34%). Nonetheless, the magnitude of inhibition did not differ with CEE, OS, or OS + CEE (Table 2) . In addition, maximal responses or sensitivity to carbachol did not vary among treatments (Table 2) , and KCl-induced contractions (an index of nerve-independent muscle contraction) were similar among treatment groups (Table 2) .
Contractile function of the EUS was explored in depth. Twitch tension (an index of single fiber function) and muscle fatigue were quantified in sphincters from all treatment groups (Table 3 ). In agreement with results using maximal field stimulation, twitch tension and fatigability were similar among treatment groups. Taken together, our results indicate that vaginal CEE, OS, or OS + CEE treatment for 3 weeks did not alter contractility of the lower urinary tract in vitro. Next, we considered the possibility that, although these hormonal regimens may not have direct impact on contractile function, they may alter the epithelial lining of the lower urinary tract and thereby function to protect the lower urinary tract from microbial invasion or affect epithelial-mesenchyme interactions. Thus, serial cross-sections (1 mm) of the lower genito-urinary tract were examined histologically for alterations in urethral morphology. At the level of the EUS, morphology of the urethral internal and external sphincters was similar in all treatment groups (Figure 2) . Likewise, the urethral lumen was lined by normal urothelium in all groups (Figure 3 ).
Effect of ospemifene and vaginal conjugated equine estrogens on the vaginal wall Uterine and vaginal weight/structure
In agreement with previous studies (12) , application of topical CEE increased vaginal weight (Supplemental Figure 1A) . In contrast, the SERM OS, alone, did not increase vaginal weight, but OS-CEE combination augmented its effect on vaginal weight. Vaginal CEE or OS alone did not increase uterine weight. Uterine weights, however, were increased significantly in the OS-CEE group relative to placebo (Supplemental Figure 1B) , suggesting the possibility of long-term risks of uterine hyperplasia. This increase in uterine weight was not due to an increase in endometrial thickness at this early time point (Supplemental Figure 1C) .
Biomechanical properties
Previously, we found that vaginal CEE resulted in decreased stiffness (i.e., increased distensibility) of the vaginal wall compared with placebo treatment [12] . To determine if OS or OS + CEE altered the biomechanical properties of the vaginal, stress-strain relationships were conducted on rings of vaginal tissue obtained at the mid-vagina from animals treated with placebo, vaginal CEE, OS, or CEE + OS. Maximal distention of tissues from all groups was ∼4 mm ( Figure  4A ). Stiffness was decreased significantly in vaginal tissues from animals treated with vaginal CEE and OS-CEE ( Figure 4B ). Stiffness was also decreased in vaginal tissues from animals treated with OS, but OS-induced decreases in stiffness were not as profound as those with CEE or OS-CEE. Decreases in stiffness were accompanied by decreased maximal strength ( Figure 4C ). The results indicate that vaginal CEE or OS-CEE results in increased vaginal wall distensibility at the expense of compromised strength.
Collagen content
Collagen content of the vaginal wall was quantified using hydroxyproline assays. To account for increased organ size, data were expressed as microgram per vagina. Amounts of collagen in fractions representing newly synthesized or denatured collagen were similar in vaginal muscularis from all treatment groups ( Figure 5A and B) . A trend for increased amount of mature, cross-linked collagen was observed in vaginal muscularis from animals treated with vaginal CEE ( Figure 5C ), and the percent of cross-linked collagen was increased in tissues from CEE compared to relatively lower content of crosslinked collagen in the placebo group ( Figure 5D ). Taken together, results indicate that short-term treatment with vaginal CEE, OS, or both did not have appreciable effects on collagen content of the vaginal wall, except modest increases in cross-linked collagen with CEE alone. Although vaginal CEE or OS alone did not alter mRNA levels of collagen type 1 or 3 mRNA or protein, combination treatment with OS + CEE resulted in downregulation of collagen mRNA but no effect on protein levels (Supplemental Figure 2) .
Vaginal epithelium
Histologic analysis revealed increased thickness of the vaginal epithelial layer for all treatment groups relative to placebo ( Figure 6A) . Importantly, epithelial thickness of vaginas from animals treated with OS-CEE was increased significantly compared with either CEE or OS alone. Lamina propria thickness was not different among groups ( Figure 6B ). The effects of OS and vaginal CEE on vaginal epithelial morphology were unique. Ovariectomy resulted in loss of the vaginal epithelium with only 1-2 cells of basal cells remaining ( Figure 6C ). In agreement with previous studies, vaginal CEE treatment resulted in orderly proliferation of basal epithelial cells, induction of epithelium stratification, hyperkeratosis, and cornification ( Figure 6C ) (11) . In contrast, the epithelium of OS-treated animals was characterized by a single layer of polarized basal epithelial cells, a blunted stratified layer with no cornification, and an irregular array of superficial mucus-secreting columnar epithelium in various stages of columnar epithelial differentiation. Perhaps the most interesting aspect of hormone-induced changes in epithelial morphology was the effect of OS + CEE ( Figure 6C ). The mucosa was comprised of proliferative basal epithelial cells and partial stratification (CEE effect) with dramatic uniform differentiation of epithelial cells to mucus-laden columnar epithelial cells (OS effects). These columnar epithelial cells were larger and more numerous compared with OS alone.
Vaginal muscularis
Next, we determined if OS or vaginal CEE altered histomorphology of the fibromuscular layer. Thickness of muscularis ( Figure 7A ) and total vaginal wall ( Figure 7B ) was not different among treatment regimens. Interestingly, however, morphology of vaginal smooth muscle differed among groups. After ovariectomy and treatment with placebo alone, smooth muscle bundles were small, diffuse, and infiltrated with collagen ( Figure 7C ). In contrast, after treatment with vaginal CEE alone, smooth muscle bundles were obviously larger, well organized, and distinctly oriented in longitudinal and circular muscle ( Figure 7C ). The effects of OS were similar, but less dramatic, than CEE. Combination therapy revealed rescue of the disordered smooth muscle bundles consistent with changes observed with CEE alone ( Figure 7C ).
Effect of ospemifene and alternative estrogen receptor agonist-antagonists on vaginal epithelium
Next, we explored the possibility that OS and CEE differentially activate ER subtypes and thereby alter epithelial differentiation pathways. To determine if OS-induced effects on the vaginal epithelium were mediated through ERβ, OS was administered together with a systemic ERβ antagonist, THC (recognizing that high doses of THC may also serve as an agonist for ERα) ( Figure  8 ). Ospemifene-induced effects were not altered by the ERβ antagonist and were not mimicked by the systemic ERβ agonist, DPN ( Figure 8C and E) . Further, the ERα antagonist MPP resulted in disruption of OS-induced effects on the epithelium with decreased mucus-laden cells and disorganization of the mucus-secreting bilayer ( Figure 8D ). PPT, an ERα agonist, produced histologic effects similar to CEE with a stratified squamous epithelial layer with cornification ( Figure 8F ). Results with systemic ERAAs were confirmed with local application (not shown). Thus, these experiments suggest that OS-induced effects on the vaginal epithelium are not mediated through ERβ. Although the effects of MPP, a well-described ERα antagonist, suggest that the effects of OS are partially mediated through ERα, it is clear that the major effects are mediated possibly through other pathways in which ERs selectively recruit coactivators and corepressors in different cell types [24] .
Discussion
Both the lower female genital and urinary tracts arise from the primitive urogenital sinus in which estrogen receptors (α and β) are expressed during development and in adult tissues of the vagina, urethra, bladder, and surrounding pelvic floor musculature [25] [26] [27] . Local intravaginal estrogen in postmenopausal women by any delivery system (creams, tablets, estrogen-containing rings) is known to decrease vaginal pH, increase blood flow, improve tissue compliance, and promote vaginal cell maturity [28] . Reviews and studies of other pelvic floor disorders commonly linked with loss of estrogen and urogenital atrophy observed in postmenopausal women (dryness, pruritus, pain/dyspareunia [29] [30] [31] , recurrent cystitis [16, 17] ) generally demonstrate improvement in symptoms and quality of life using local estrogen in the form of CEE or 17β-estradiol [28, 30, 32, 33] . Nevertheless, adherence to vaginal treatment is poor due to fear of systemic absorption or discomfort with application [34, 35] . Thus, alternatives to estrogen and topical application have been developed including introduction of the SERM, ospemifene, in oral form, to relieve dyspareunia related to VVA in postmenopausal women [9] . Its tissue specificity profile makes it an ideal therapy for women with contraindications to estrogen. Very little is known regarding effects of OS on the lower urinary tract and symptoms often accompanying VVA, including urinary urgency, frequency, and incontinence. Further, only one prior preclinical study has reported OS-induced changes in the vaginal epithelium [11] , and did not include comparisons to vaginal CEE, the more common formulation for VVA.
Differential responses of the vagina to local conjugated equine estrogens or ospemifene
Previously, we used the ovariectomized menopausal rat model to find that vaginal CEE was superior to systemic estrogen (either 17β-estradiol or oral CEE) in terms of increasing epithelial thickness [12] . Experiments reported herein were conducted in ovariectomized animals treated for 3 weeks. In agreement with animals treated for 4 weeks [12] , vaginal CEE increased epithelial thickness and morphologic changes of stratified cornified epithelium. The effects of OS differed significantly and OS-CEE exhibited synergistic effects. Importantly, OS-CEE also resulted in increased uterine weight. In this short-term study, this was not associated with increased endometrial thickness. Nonetheless, longer term administration of combination therapy may lead to significant endometrial hyperplasia and safety trials need to be completed prior to clinical use of combination therapy. The mechanisms of these different effects on vaginal epithelial morphology and differentiation are not known. Estrogen receptor α and β are highly expressed in the basal cells of the stratified squamous epithelium of the vagina which include continuously dividing germinal cells and their offspring as they migrate toward the lumen where they are ultimately shed [36] .
Effects of systemic and vaginal estrogen receptor agonist-antagonists
Given the drastic differences in vaginal epithelial histomorphology with CEE and OS, we sought to further explore the possibility that these agents differentially activate ER subtypes. Specifically, we hypothesized that the morphologic changes of the vaginal epithelium observed with OS and CEE treatment were mediated by ERβ and ERα, respectively. Although not known in the case of OS, other investigators have suggested that the differential vaginal epithelial differentiation displayed by lasofoxifene (an alternate SERM) may be mediated via induction of androgren receptor and ER-β. [37] . Two ER antagonists were used to study OS-induced ER activation: THC for ERβ [38, 39] and MPP as a selective, high-affinity antagonist of ERα [40, 41] . Two ER agonists were used to determine if activation of these ERs mimicked OS effects on the vaginal epithelium: DPN as an ERβ-selective agonist (70-fold higher binding compared to ERα) [42] and PPT as an ERα-selective agonist with 410-fold binding affinity for ERα vs. ERβ [43] . The results of these experiments (both vaginal and systemic formulations) demonstrated that administration of the ERβ antagonist, THC, did not block OS-mediated effects on the vaginal epithelium, suggesting that the effects of OS are mediated through pathways independent of ERβ. Administration of the ERα agonist, PTT, mimicked the effects of CEE, but not OS, indicating that vaginal CEE acts predominantly through vaginal ERα. The ERα antagonist, MPP, however, caused modest disruption of OS-induced epithelial mucinproducing cells suggesting that OS-induced effects are at least partially mediated through ERα but that the major effects of OS were mediated through other pathways [44] . In general, the activity of SERMs is determined by the selective recruitment of coactivators and corepressors in different cell types and tissues [24] . Therefore, the specific effects of OS on the vaginal epithelium are likely due to epithelial cell-and promoter-specific differences in coregulatory recruitment of ER-regulated genes.
Collagen and biomechanics
In contrast to 4 weeks of vaginal CEE [12] , collagen content was not altered in the vaginal muscularis after 3 weeks of vaginal CEE treatment. Since collagen protein turnover is relatively slow, longer treatment times may be required for estrogen-induced maximal strength and increases in collagen content. Our findings of increased amounts of cross-linked collagen in the vaginal CEE group support this possibility. It is somewhat paradoxical that vaginal stiffness decreased significantly with vaginal CEE and OS without appreciable changes in collagen content. Although it is well known that tissue stiffness is largely dictated by collagen content, it is also modified by collagen organization through collagen-binding proteoglycans, glycosaminoglycans, or elastic fibers. This study indicates that vaginal CEE induces changes in biomechanical properties independent of collagen content. Further, OS was not as effective as vaginal CEE in increasing vaginal distensibility and opposed CEE-induced effects on the viscoelastic properties of the vaginal wall.
Lower urinary tract
Urinary symptoms commonly emerge with the onset of menopause [45] . Information regarding estrogen and urinary incontinence in postmenopausal women indicates disparate effects depending on systemic vs. local estrogen delivery [46] . Six trials of systemic estrogen demonstrate worse incontinence compared with placebo whether with systemic CEE alone (Relative odds ratio 1.32, 1.17-1.48) or if combined with progesterone (RR 1.11, 1.04-1.18). In contrast, with local application (creams and pessaries), incontinence rates improve (RR 0.74, 0.64-0.86), and OAB symptoms of urgency (RR 0.38, 0.15-0.99) and frequency improve with estrogen. Further, a recent randomized trial of local 17β-estradiol vs. an oral anticholinergic medication (oxybutynin) for treatment of OAB in postmenopausal women demonstrated similar effectiveness in decreasing number of daily voids and improvements in disease-specific quality of life [14] . Furthermore, clinical trials in humans using vaginally administered estrogens in the form of estradiol or estriol support improvement of OAB-related symptoms such as urgency, frequency, and nocturia [47, 48] . Effects of local estrogen on stress urinary incontinence are not well characterized, but local CEE has been shown to decrease the pulsatility index in the urethral vascular network (indicating greater blood flow) and improve subjective stress incontinence bother in 60% of women [49] .
Animal studies suggest that estrogen inhibits Rho-kinase in bladder smooth muscle, affecting smooth muscle contraction [50] . Another ovariectomized rat model of menopause demonstrated increased 24-h urinary frequency and decreased voided amount, associated with increased basal and stretch-induced acetylcholine release, changes that were reversed by systemic 17β-estradiol replacement [51] . In contrast, the effects of SERMs, and specifically OS, on the lower urinary tract are less understood. In this study, vaginal CEE, OS, or CEE-OS did not alter nerve-dependent or innervationindependent contractile function of smooth muscles of the bladder neck and dome. Responses to cholinergic stimulation were also independent of estrogen status. Further, striated muscle function of the EUS was not altered by treatment regimen.
In contrast to dramatic effects on vaginal epithelium, urethral epithelial cells did not differ among treatment groups. The urothelium not only forms a high-resistance barrier to ion, solute and water flux, and pathogens, but also functions as an integral part of a sensory web that receives, amplifies, and transmits information about its external milieu [52] . In the rat, the distal urethral epithelium was similar to that of the proximal urethra. In humans, the distal urethra is lined by mucosa indistinguishable from vulvovaginal epithelium [53] . It is possible, therefore, that humans may respond to estrogens or OS by alteration of urothelial mucosal signaling [54] which is absent in the rat.
Summary
Collectively, our data suggest that the actions of OS are complex and differ significantly from vaginal estrogens. Ospemifene alters the epithelium in a unique way that is additive with local CEE. In contrast, OS opposes the positive effects of CEE on vaginal distensibility. Contractile responses of the bladder neck, bladder dome, and EUS were not altered by treatment with vaginal estrogen, OS, or combination therapy. These results suggest that, unless contraindicated, the beneficial effects of vaginal CEE on the vaginal wall outweigh those of OS. Although the combination of OS-CEE may be an alternative treatment for severe VVA refractory to either agent alone, this treatment cannot be recommended without additional safety data which are not available at this time.
